Biopsy and personalized medicine

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 11, 2012, Pages 683-

  Amalou, Hayet ^a   Wood, Bradford J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; TUMOR MARKER;

BIOPSY; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; FUSION GUIDED BIOPSY; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL STROMAL TUMOR; GENETIC MARKER; HUMAN; LETTER; LIVER CANCER; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PANCREATITIS, CHRONIC; PHARMACOGENETICS;

EID: 85027940528     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.100-c1     Document Type: Letter

References (9)

1. Whitcomb, D. C. What is personalized medicine and what should it replace? Nat. Rev. Gastroenterol. Hepatol. 9, 418-424 (2012).
2. Krücker, J. et al. Electromagnetic tracking for thermal ablation and biopsy guidance: clinical evaluation of spatial accuracy. J. Vasc. Interv. Radiol. 18, 1141-1150 (2007). (Pubitemid 47332231)
3. Kruecker, J. et al. Clinical utility of real-time fusion guidance for biopsy and ablation. J. Vasc. Interv. Radiol. 22, 515-524 (2011).
4. Pinto, P. A. et al. Magnetic resonance imaging/ ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J. Urol. 186, 1281-1285 (2011).
5. Venkatesan, A. M. et al. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology 260, 848-856 (2011).
6. Abi-Jaoudeh, N. et al. Cone-beam computed tomography fusion and navigation for real-time positron emission tomography-guided biopsies and ablations: A feasibility study. J. Vasc. Interv. Radiol. 23, 737-743 (2012).
7. Posadas, E. M. et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109, 1323-1330 (2007). (Pubitemid 46466559)
8. Annunziata, C. M. et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin. Cancer Res. 16, 664-672 (2010).
9. Rutman, A. M. & Kuo, M. D. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur. J. Radiol. 70, 232-241 (2009).